NovoCure (NASDAQ:NVCR) Ltd. is a global oncology company focused on developing and commercializing a novel therapy platform known as Tumor Treating Fields (TTFields), which uses low-intensity, alternating electric fields to disrupt cancer cell division. The company’s proprietary medical devices deliver TTFields through transducer arrays placed on the patient’s skin, targeting specific tumor locations. NovoCure’s lead products, marketed under the Optune brand, are used primarily in the treatment of glioblastoma and other solid tumor indications, offering a non-invasive option that complements existing chemotherapy and radiotherapy regimens.
Founded in 2000 by Dr. Yoram Palti, a bioengineer at the Technion–Israel Institute of Technology, NovoCure has headquarters in Jersey City, New Jersey, and maintains research facilities in Israel. The company’s multidisciplinary teams in engineering, oncology, and clinical operations work in concert to advance TTFields therapy across a range of tumor types. NovoCure generates revenues through device leasing agreements and provides comprehensive patient support services, including training, monitoring, and reimbursement assistance to ensure optimal therapy adherence and outcomes.
Since its first regulatory clearance in Europe in 2011 and U.S. Food and Drug Administration approval in 2015, NovoCure has expanded its clinical program to include multiple Phase III trials in mesothelioma, non-small cell lung cancer, pancreatic cancer and ovarian cancer. The company collaborates with leading cancer centers and academic institutions worldwide, contributing to a growing body of clinical data that supports the efficacy and safety profile of TTFields. Ongoing research explores combination strategies with immunotherapies and targeted agents to further enhance patient benefit.
Today, NovoCure markets its therapy in more than 80 countries, with commercial operations spanning North America, Europe, Asia-Pacific and Greater China. Asaf Danziger, who serves as Chief Executive Officer, leads the company’s strategic initiatives and global expansion efforts. Supported by a board of directors that includes its founder, Dr. Palti, NovoCure continues to pursue regulatory approvals, pipeline development and partnership opportunities aimed at transforming the standard of care for patients with solid tumor cancers.
